Clinical DevelopmentEncouraging data in a broad range of solid tumors, including breast, pancreatic, and colorectal cancers, providing proof-of-concept that pelareorep induces remodeling of the tumor microenvironment and elicits tumor-directed immune responses.
Financial StabilityManagement believes its current cash balance, including its previously reported C$40M cash position, together with grant funding from the PanCAN provides over 12 months of runway for its operations.
Strategic CollaborationsManagement expressed optimism regarding a potential clinical path forward that includes a collaboration with a major biopharmaceutical company.